Locally advanced vs. metastatic disease, and how uncommon each one is
Bring a printable list of questions to your appointment, or share this page with someone who needs it.
Cutaneous squamous cell carcinoma (SCC) is the second most common skin cancer, and for the great majority of people who develop one, treatment is straightforward: a dermatologist removes it in a single office procedure and it never returns. So it can be unsettling to hear a doctor call an SCC "advanced."
"Advanced SCC" is not a single stage number. It is a practical label for the small minority of squamous cell carcinomas that can no longer be handled with routine surgery. It covers two different situations — one much more common than the other — and knowing which one applies to you shapes the entire conversation about treatment.
This page explains what each term means, how doctors decide a tumor has crossed that line, and why the label matters. For the specific point at which surgeons and radiation oncologists step back, see when surgery and radiation are no longer enough. For how doctors sort ordinary SCCs from concerning ones in the first place, see SCC staging and grading.
When clinicians and treatment guidelines say "advanced SCC," they are grouping together two distinct problems that happen to be treated with the same systemic medications:
The tumor has grown large or deep, invaded nerves, muscle, cartilage, or bone, or come back after previous treatment — to the point where surgery or radiation can no longer clear it without unacceptable loss of function or disfigurement, or it is considered inoperable. It has not spread elsewhere. This accounts for the large majority of advanced cases.
The cancer has traveled beyond the skin — most often to nearby (regional) lymph nodes, and less commonly to the lungs, liver, or bone. It is treated with the same drugs used for locally advanced disease. When spread is limited to regional nodes and can be removed or irradiated, the outlook is meaningfully better than with distant spread.
Locally advanced SCC is defined less by a single measurement and more by a judgment: could this tumor be removed with surgery, or treated with radiation, and still leave the patient with a reasonable outcome? When the honest answer is no, the tumor is considered locally advanced. Features that push an SCC into this category include:
Most people who reach this point got there over months to years — a tumor that was ignored, dismissed as a sore that would not heal, or treated repeatedly without changing the approach. It is uncommon, but it is also, in hindsight, usually preventable. Many of these same features are what doctors mean by a "high-risk" SCC, and perineural invasion in particular changes how a tumor is treated.
Most cutaneous SCCs never spread. Estimates vary with how studies are done, but across all comers only a few percent — most figures fall between roughly 2% and 5% — ever reach the lymph nodes, and deaths from the disease are less common still. Because SCC is so common overall, however, those small percentages still add up to thousands of cases a year in the United States.
Spread is far more likely when a tumor carries high-risk features — large size, deep invasion, poor differentiation, or perineural invasion — or when it arises in someone who is immunosuppressed, such as an organ transplant recipient. The first stop is almost always the regional lymph nodes (in front of the ear, in the neck, the armpit, or the groin, depending on where the tumor is); distant organs are involved much less often.
For a fuller picture of what raises the odds of spread, and how nodes are checked, see recurrence and metastasis risk and nodal metastasis and sentinel node biopsy.
There is no single blood test or scan that returns an "advanced" result. The determination is made by a team looking at the whole picture:
Guidelines recommend that these hard cases be reviewed by a multidisciplinary tumor board rather than decided by one clinician alone. The details of that evaluation are covered in how advanced SCC is evaluated before treatment.
The reason "locally advanced" and "metastatic" are grouped together is that once an SCC cannot be cured by cutting it out or irradiating it, the treatment strategy is similar for both: medication that circulates through the whole body, sometimes combined with surgery or radiation.
"Advanced" squamous cell carcinoma is a small corner of a very common disease. It means one of two things: a tumor that has grown or recurred beyond what surgery and radiation can fix, or one that has spread beyond the skin — usually to nearby lymph nodes first. The first is uncommon; true metastasis is uncommon still, and much of the risk is concentrated in tumors with recognizable high-risk features.
Either way, the diagnosis is not the dead end it once was. Immunotherapy now gives people with advanced cutaneous SCC real, durable options, and the right next step usually begins with a team that treats these tumors regularly.
Disclaimer: This article is for educational purposes only and not a substitute for professional medical advice. Always consult a qualified dermatologist or oncologist about your personal diagnosis and treatment plan.
Chat with our AI guide for information about advanced squamous cell carcinoma
Chat with the Navigator